Showing 5041-5050 of 6808 results for "".
- Demystifying Itch: Does S. aureus Kickstart a Molecular Chain Reaction That Culminates in the Urge to Scratch?https://practicaldermatology.com/news/demystifying-itch-does-s-aureus-kickstart-a-molecular-chain-reaction-that-culminates-in-the-urge-to-scratch/2462148/Staphylococcus aureus may cause itch by acting directly on nerve cells. The findings, based on research in mice and in human cells, are reported Nov. 22 in Cell. In eczema and atopic dermatitis, the equilibrium of microorganisms that keep skin he
- AD Pipeline Watch: Rademikibart Maintains Efficacy Out to Week 52https://practicaldermatology.com/news/ad-pipeline-watch-rademikibart-maintains-efficacy-out-to-week-52/2462145/Connect Biopharma’s rademikibart continues to wow in patients with moderate-to-severe atopic dermatitis, according to topline results from the Stage 2 (maintenance period) of its China pivotal trial. Rademikibart is an inhibitory human monoclonal antibody against the IL-4Rα
- Strength in Numbers: IPC, IFPA, and ILDS Presidents Sign Letter of Commitmenthttps://practicaldermatology.com/news/strength-in-numbers-ipc-ifpa-and-ilds-presidents-sign-letter-of-commitment/2462144/Hervé Bachelez, MD, PhD, President of the International Psoriasis Council (IPC), Hoseah Waweru, MD, President of the International Federation of Psoriasis Associations (IFPA), and Henry W. Lim MD, President of the International League of Dermatological Societies (ILDS) recently signed a le
- How Does Social Media Influence Patients’ Understanding of Dermatologic Information?https://practicaldermatology.com/news/examining-social-medias-influence-on-patients-understanding-of-dermatologic-information/2462143/Social media users trust what’s out there about dermatologic conditions and make healthcare decisions based on this information for better or for worse, according to research presented at the 2nd Annual Dermatology Therapeutics Symposium (DTS) in Austin, Texas. “Healthcare professionals h
- New Deadline: Allergan Aesthetics, University Lab Partners Launch Golden Passport Pitch Competition to Accelerate Aesthetics Start-Upshttps://practicaldermatology.com/news/news-you-can-use-allergan-aesthetics-university-lab-partners-launch-golden-passport-pitch-competition-to-accelerate-aesthetics-start-ups/2462091/University Lab Partners (ULP) and Allergan Aesthetics are launching the Golden Passport pitch competition for aesthetic startups. The Golden Passport provides the winner with a lab bench for one year and opportunities to engage with industry mentors including scientific and business lea
- European Commission Approves EBGLYSS (Lebrikizumab) for Moderate-to-severe ADhttps://practicaldermatology.com/news/european-commission-approves-ebglyss-lebrikizumab-for-moderate-to-severe-ad/2462141/The European Commission has approved EBGLYSS (lebrikizumab) for the treatment of adult and adolescent patients (12 years and older with a body weight of at least 40 kg) with moderate-to-severe atopic dermatitis (AD), who are candidates for systemic therapy. Almirall will
- Phase 1 Data: Kymera Therapeutics’ IRAK4 Degrader Shows Promise in AD, HShttps://practicaldermatology.com/news/phase-1-data-kymera-therapeutics-irak4-degrader-shows-promise-in-ad-hs/2462133/Kymera Therapeutics, Inc. KT-474 (SAR444656), a potent, highly selective, orally bioavailable IRAK4 degrader, is showing early promise in Hidradenitis Suppurativa (HS) and Atopic Dermatitis (AD), according to a Phase 1 Trial
- Is Lower Extremity Lymphedema a Risk for Skin Cancer?https://practicaldermatology.com/news/is-lower-extremity-lymphedema-a-risk-for-skin-cancer/2462127/Patients with lymphedema may have twice the risk of developing basal cell carcinomas and squamous cell carcinomas on the lower extremities than their counterparts without lymphedema, according to a retrospective study published in the November 2023 issue of the Mayo Clinic Proceedings.&n
- CeraVe Launches in Indiahttps://practicaldermatology.com/news/cerave-launches-in-india/2462126/L'Oréal Dermatological Beauty recently unveiled CeraVe in India. To support the launch, the brand hosted 'Skin Barrier Science - A Dermatological Summit' in Mumbai, with dermatologists, experts, and partners from all over India and t
- FDA Approves Cosentyx for HShttps://practicaldermatology.com/news/fda-approves-cosentyx-for-hs/2462109/The US Food and Drug Administration (FDA) has given its nod to Novartis’ Cosentyx (secukinumab) to treat moderate to severe hidradenitis suppurativa (HS) in adults. The IL-17A inhibitor is the first new biologic treatment option for HS patients in nearly a decade.</